These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 36106123)
1. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer. Feng A; He L; Chen T; Xu M Front Oncol; 2022; 12():957966. PubMed ID: 36106123 [TBL] [Abstract][Full Text] [Related]
2. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs. Tu H; Zhang Q; Xue L; Bao J Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481 [TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H Front Genet; 2022; 13():938259. PubMed ID: 35910212 [No Abstract] [Full Text] [Related]
6. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
7. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation. Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J Front Oncol; 2022; 12():1030802. PubMed ID: 36620545 [TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
9. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
10. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia. Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F Front Oncol; 2022; 12():966920. PubMed ID: 36276132 [TBL] [Abstract][Full Text] [Related]
11. Identification of cuproptosis-associated IncRNAs signature and establishment of a novel nomogram for prognosis of stomach adenocarcinoma. Yu W; Huo H; You Z; Lu R; Yao T; Huang J Front Genet; 2022; 13():982888. PubMed ID: 36160008 [No Abstract] [Full Text] [Related]
12. A novel prognostic signature based on cuproptosis-related lncRNA mining in colorectal cancer. Hou D; Tan JN; Zhou SN; Yang X; Zhang ZH; Zhong GY; Zhong L; Yang B; Han FH Front Genet; 2022; 13():969845. PubMed ID: 36105091 [No Abstract] [Full Text] [Related]
13. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer. Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X Front Genet; 2023; 14():1096783. PubMed ID: 36911392 [No Abstract] [Full Text] [Related]
14. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related]
15. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related]
16. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer. Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089 [No Abstract] [Full Text] [Related]
17. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis. Li D; Wu X; Song W; Cheng C; Hao L; Zhang W Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675 [TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z Front Genet; 2022; 13():947551. PubMed ID: 35938003 [No Abstract] [Full Text] [Related]
20. Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer. Wang Q; Xu Y Front Pharmacol; 2022; 13():1065701. PubMed ID: 36532719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]